Detecting early chronic kidney disease: Are clinical laboratories a problem?

American Journal of Kidney Diseases

Volumn 42, Issue 2, 2003, Pages 392-394

  Hostetter, Thomas H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTEIN;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL LABORATORY; COST; COST CONTROL; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG COST; EARLY DIAGNOSIS; ECONOMIC ASPECT; EDITORIAL; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MEASUREMENT; MICROALBUMINURIA; MONITORING; NEPHROLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROPHYLAXIS; PROTEIN URINE LEVEL; PROTEOMICS; QUALITY OF LIFE; RENAL DIABETES; SCREENING;

EID: 0042126907     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(03)00689-9     Document Type: Editorial

References (20)

1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41:1-12, 2003
2. Harwell TS, Nelson RG, Little RR, McDowall JM, Helgerson SD, Gohdes D: Testing for microalbuminuria in 2002: Barriers to implementing current guidelines. Am J Kidney Dis 42:245-248, 2003
3. Verstappen WH, van der Weijden T, Sijbrandij J, et al: Effect of a practice-based strategy on test ordering performance of primary care physicians: A randomized trial. JAMA 289:2407-2412, 2003
4. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
5. Kasiske BL: The kidney in cardiovascular disease. Ann Intern Med 134:707-709, 2001
6. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342:381-389, 2000
7. Borch-Johnsen K, Wenzel H, Viberli GC, Mogensen CE: Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 306:1722-1725, 1993
8. Klonoff DC, Schwartz DM: An economic analysis of interventions for diabetes. Diabetes Care 23:390-404, 2000
9. Palmer AJ, Weiss C, Sendi PP, et al: The cost-effectiveness of different management strategies for type I diabetes: A Swiss perspective. Diabetologia 43:13-26, 2000
10. Siegel JE, Krolewski AS, Warram JH, Weinstein MC: Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol 3:S111-S119, 1992
11. Trivedi HS, Pang MM, Campbell A, Saab P: Slowing the progression of chronic renal failure: Economic benefits and patients' perspectives. Am J Kidney Dis 39:721-729, 2002
12. Scheid DC, McCarthy LH, Lawler FH, Hamm RM, Reilly KE: Screening for microalbuminuria to prevent nephropathy in patients with diabetes: A systematic review of the evidence. J Fam Pract 50:661-668, 2001
13. Kiberd BA, Jindal KK: Screening to prevent renal failure in insulin dependent diabetic patients: An economic evaluation. BMJ 311:1595-1599, 1995
14. American Diabetes Association: Diabetic nephropathy. Diabetes Care 25:S85-S89, 2002
15. Eknoyan G, Bakris GL, Hebert L, et al: Proteinuria and other markers of chronic kidney disease: A position statement of the National Kidney Foundation and the National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis (in press)
16. K/DOQI guidelines on blood pressure management and use of antihypertensive agents in chronic kidney disease. Am J Kidney Dis (in press)
17. The Seventh Report of the Joint National Commission on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: National Heart, Lung, and Blood Institute. May 2003. NIH Publication No. 03-5233.
18. Coresh J. Astor BC, McQuillan G, et al: Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 39:920-929, 2002
19. Golan L, Birkmeyer JD, Welch HG: The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 131:660-667, 1999
20. Kiberd BA, Jindat KK: Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: An economic evaluation, Am J Kidney Dis 31:49-54, 1998